Lung Caner study 1:
Study name:
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04736173)
Eligibility:
Participants with locally advanced disease, treatment naïve and must not be eligible to receive other potentially curative therapies.
Treatment 1:
Zimberelimab (AB122) and Domvanalimab
Treatment 2:
Pembrolizumab
Lung Caner study 2: (Completed recruitment)
Study name:
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Eligibility:
Patients with unresectable, locally advanced or metastatic NSCLC with KRAS G12C mutation and disease progression on or after treatment with a platinum-based regimen and an immune checkpoint inhibitor.
Treatment 1:
MRTX849
Treatment 2:
Docetaxel